COMP <GO>
SOLV vs ABBV // FREE CASH FLOW YIELD
Solventum Corporation (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: SOLV 5
— ABBV 10
▲ FREE CASH FLOW YIELD LEADER: ABBV
LAST: $81.33 (-2.67%) • MKT CAP: $14.22B
fcf-yield
-0.07%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SOLV VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SOLV | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 53.50% | 70.20% | -16.70 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.70% | 29.00% | -10.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.3x | 33.3x | -26.00 | SOLV | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -0.07% | 3.47% | -3.54 | ABBV | /fcf-yield <GO> |
| Operating Margin | 26.20% | 24.60% | +1.60 | SOLV | /operating-margins <GO> |
| Net Profit Margin | 18.70% | 6.90% | +11.80 | SOLV | /net-margins <GO> |
| Revenue Growth (YoY) | 0.90% | 8.60% | -7.70 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.25 | 5.33 | -3.08 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.40% | -0.30 | SOLV | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.3 | 72.8 | -37.53 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 1.15 | -0.09 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | 113.1x | -104.60 | SOLV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.22B | $513.86B | -$499.64B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SOLV REV | ABBV REV | SOLV GROSS % | ABBV GROSS % | SOLV FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.32B | $61.16B | 53.5% | 70.2% | -$10.0M | $17.82B |
| FY 2024 | $8.25B | $56.33B | 55.6% | 70.0% | $805.0M | $17.83B |
| FY 2023 | $8.20B | $54.32B | 44.0% | 44.0% | $1.55B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SOLV // BETA 1.06
ABBV // BETA 1.15